<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyTrialSummaryOutput xmlns:ns2="local" id="275604"><Title>Prostvac in Combination With Nivolumab in Men With Prostate Cancer</Title><Indications><Indication>Prostate tumor</Indication><Indication>Hormone refractory prostate cancer</Indication></Indications><Phase>Phase 1/Phase 2 Clinical</Phase><Drugs><Drug>rV-PSA + rilimogene glafolivec prime-boost prostate cancer vaccine, Therion</Drug><Drug>nivolumab</Drug></Drugs><RecruitmentStatus>Recruiting</RecruitmentStatus><Sponsor>National Cancer Institute</Sponsor></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyTrialSummaryOutput>